- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02622282
Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease
Text Messaging to Promote Walking Among Latino Adults at Risk for PAD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Thirty-five million Latinos live in the U.S. and nearly 14% have peripheral arterial disease (PAD) defined as a build-up of plaque in the arteries that supply blood to the legs. Approximately 40% have at least one risk for PAD (i.e., aged 70 years and older, diabetes, high blood pressure, high blood cholesterol, or smoking). Persons with at least one risk factor and who are physically inactive are more likely to suffer from severe PAD. Physical inactivity is highly prevalent in Latinos and a major risk factor for PAD. Physical inactivity affects 50% of Latinos aged 60 years and older.
Participation in this study will last for about 3 months. Participants will be randomized to one of two groups. One group will receive text messages, brief telephone calls, and a handout. The other group will only receive the handout. The study will be looking at how the different groups respond to the different interventions used in the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- KU School of Medicine - Wichita
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Latino adults
- English or Spanish speaking
- Have one or more of the following: diabetes mellitus, smoking, hypertension, or hyperlipidemia.
- Adults age 70 years or older, regardless of having one or more the above noted risk factors for PAD, will also be eligible for enrollment.
Exclusion Criteria:
- Pregnancy
- Prior major amputation (foot or lower leg) or critical leg ischemia (tissue loss, gangrene, or ulcers)
- Use of supplemental oxygen
- Myocardial infarction within preceding 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental Group
Participants will receive text messages and telephone calls during the length of their participation.
Participants will receive a handout with information on PAD and physical activity.
|
Text messages will be sent one time per day.
Text messages will include messages to motivate and inform participants on the importance of walking.
Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
Handout includes information specific to participant's condition and ways to promote an active lifestyle.
|
|
Active Comparator: Control Group
Participants will receive a handout with information on PAD and physical activity.
|
Handout includes information specific to participant's condition and ways to promote an active lifestyle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Physical Activity
Time Frame: Change from Baseline to 3 Months
|
All participants will use a pedometer.
Mean change will be measured based on steps per day.
|
Change from Baseline to 3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Exercise Behavior
Time Frame: Change from Baseline to 3 Months
|
Change will be measured using the Exercise Behaviors Survey.
|
Change from Baseline to 3 Months
|
|
Change in Quality of Life
Time Frame: Change from Baseline to 3 Months
|
Change will be measured using the Medical Outcomes Study (MOS) Short Form 36.
The survey has 36 questions.
Scores are coded based on response by participant.
A score of 100 indicates the most favorable situation while a score of 0 would indicate the least favorable.
|
Change from Baseline to 3 Months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tracie C. Collins, MD, MPH, University of Kansas Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00003190
- R56AG047590 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
BayerCompleted
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
Clinical Trials on Text Messages
-
Friedrich-Alexander-Universität Erlangen-NürnbergPhilipps University Marburg Medical CenterCompleted
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
Children's Hospitals and Clinics of MinnesotaHealthPartners InstituteUnknownAsthmaUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedSmoking | PregnancyUnited States
-
Medical University of South CarolinaRoswell Park Cancer InstituteCompleted
-
Auburn UniversityCompleted
-
Centre for Addiction and Mental HealthHealth CanadaCompleted
-
Imperial College LondonBarts & The London NHS Trust; Mid and South Essex NHS Foundation Trust; Royal... and other collaboratorsCompleted
-
Vanderbilt University Medical CenterCompleted
-
Columbia UniversityCompletedAtopic DermatitisUnited States